Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 139 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas
Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy
Who cites it
139 citing papers in PubMed, 4 syntheses or guidelines pooled it, 315 citations in OpenAlex.
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.Journal of the American Academy of Dermatology · 2017Pooled it
- Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Journal of the National Cancer Institute · 2016Pooled it
- Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.Journal for immunotherapy of cancer · 2020Trial
- Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study.Medicine · 2020Trial
- Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.Cancer chemotherapy and pharmacology · 2015Trial
- A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.British journal of cancer · 2014Trial
- Trial
- Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).Investigational new drugs · 2013Trial
- Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.Investigational new drugs · 2013Trial
- Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.Cancer · 2012Trial
- Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.International journal of cancer · 2011Trial
- Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series.Cancer reports (Hoboken, N.J.) · 2026Article
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Investigating Real-World Tolerance and Dose Reductions of Oncology Multikinase Inhibitors in a VA Population.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Tumor habitat characteristics derived from intravoxel incoherent motion for early response assessment in soft tissue sarcoma undergoing neoadjuvant radiotherapy and targeted therapy: a phase II study.Translational cancer research · 2026Article
- Solitary fibrous tumor: an updated review.Journal of pathology and translational medicine · 2026Article
- Advances in the multimodal management of central nervous system solitary fibrous tumors.Frontiers in oncology · 2026Review
- Mutational analysis of primary and advanced chordoma tissue using next-generation sequencing.Cancer · 2025Article
79 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
PURPOSE To evaluate the potential benefit of continuous daily dosing sunitinib in patients with advanced nongastrointestinal stromal tumor (GIST) sarcomas. PATIENTS AND METHODS A total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily. Primary end point was Response Evaluation Criteria in Solid Tumors defined response. Secondary end points were stable disease at 16 and 24 weeks. [(18)F]-fluorodeoxyglucose positron emission tomography was performed on a subset of 24 patients at baseline and after 10 to 14 days of therapy. Results Forty-eight patients were eligible for response. One patient (desmoplastic round cell tumor [DSRCT]) achieved a confirmed partial response (PR) and remained on study for 56 weeks. Ten patients (20%) achieved stable disease for at least 16 weeks. Metabolic PR was seen in 10 (47%) of 21 of patients. Metabolic stable disease was seen in 11 (52%) of 21. There were no unexpected toxicities observed. CONCLUSION Sunitinib demonstrated notable evidence of metabolic response in several patients with non-GIST sarcoma. The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.